@inbook{3ca1e7b6edc8457abd27225c5a751caa,
title = "Ventricular-Arterial Interaction in Patients with Heart Failure and a Preserved Ejection Fraction",
author = "Borlaug, {Barry A.} and Vojtech Melenovsky and Kass, {David A.}",
note = "Funding Information: Many of the increases in ventricular-arterial stiffness in HFpEF are chronic in nature, due to changes in the material properties of the cardiovascular system. 6 In the largest randomized trial of heart failure with near-normal EF (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity [CHARM]-Preserved), there was a borderline-significant treatment effect driven by a reduction in hospitalizations for heart failure. 66 However, this trial enrolled subjects with heart failure and EF greater than 40%, which is not typical of the garden-variety HFpEF patient with LVH and LV ejection fraction greater than 60%. 33, 35, 36, 44 Other therapies targeting these chronic changes include aldosterone, 67, 68 transforming growth factor-β, 69 and chymase antagonists. 70 A large-scale randomized trial funded by the National Institutes of Health was initiated in 2006 to test the efficacy of the aldosterone antagonist spironolactone in HFpEF (TOPCAT-NCT00094302). This study is ongoing. ",
year = "2008",
month = jan,
day = "1",
doi = "10.1016/B978-1-4160-3754-5.50037-8",
language = "English (US)",
pages = "403--412",
booktitle = "Diastology",
publisher = "Elsevier",
}